SC
BPMC

Schubert & Co’s Blueprint Medicines BPMC Stock Holding History

Schubert & Co’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4
Closed – – 1639
2022
Q3 		$0 Sell
4
-8
-67% -$514 ﹤0.01% 1384
2022
Q2 		$1K Buy
12
+2
+20% +$117 ﹤0.01% 1012
2022
Q1 		$1K Buy
10
+1
+11% +$72 ﹤0.01% 598
2021
Q4 		$1K Buy
+9
New +$941 ﹤0.01% 545

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Schubert & Co's BPMC Position: Q4 2022 in Review

Schubert & Co sold out of Blueprint Medicines (BPMC) in Q4 2022, closing a stake of 4 shares.

Schubert & Co first reported a position in BPMC in Q4 2021 and held it in 4 quarters. The position peaked at $1K in Q2 2022. 223 funds tracked by Wall St. Rank hold BPMC as of Q4 2022.

  • Schubert & Co reported no remaining Blueprint Medicines position as of Q4 2022 after selling out during the quarter.
  • Schubert & Co sold 4 Blueprint Medicines shares in Q4 2022.
  • Schubert & Co first reported a position in Blueprint Medicines in Q4 2021 and held it in 4 quarters.
  • Schubert & Co's Blueprint Medicines position peaked at $1K in Q2 2022.
  • 223 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2022.

Based on Schubert & Co's 13F filing for Q4 2022, filed 1 Feb 2023.